Abstract
Bleeding in acute promyelocytic leukemia (APL) is mainly associated with disseminated intravascular coagulation and hyperfibrinolysis. Annexin II (Ann II) is a co-receptor for plasminogen and tissue plasminogen activator (tPA). This study demonstrates that abnormally high levels of Ann II expression in APL cells increase the production of plasmin. Hyperfibrinolysis could be corrected by all-trans retinoic acid (ATRA) or ATRA plus arsenic trioxide therapy in patients with APL. SiRNA targetting Ann II caused a decrease in tPA-dependent plasmin generation, while Ann II cDNA transfectant stimulated plasmin production. These results suggest that Ann II play an important role in hyperfibrinolysis in APL.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Annexin A2 / antagonists & inhibitors
-
Annexin A2 / genetics
-
Annexin A2 / metabolism*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Arsenic Trioxide
-
Arsenicals / administration & dosage
-
Blood Coagulation Tests
-
Blotting, Western
-
Cell Proliferation / drug effects
-
Female
-
Fibrinolysin / metabolism
-
Fibrinolysis / drug effects
-
Fibrinolysis / physiology*
-
Flow Cytometry
-
Humans
-
Leukemia, Promyelocytic, Acute / drug therapy
-
Leukemia, Promyelocytic, Acute / metabolism*
-
Leukemia, Promyelocytic, Acute / pathology
-
Male
-
Middle Aged
-
Oxides / administration & dosage
-
Plasminogen / metabolism
-
RNA, Messenger / genetics
-
RNA, Small Interfering / genetics
-
Reverse Transcriptase Polymerase Chain Reaction
-
Tissue Plasminogen Activator / metabolism
-
Tretinoin / administration & dosage
-
Young Adult
Substances
-
Annexin A2
-
Arsenicals
-
Oxides
-
RNA, Messenger
-
RNA, Small Interfering
-
Tretinoin
-
Plasminogen
-
Tissue Plasminogen Activator
-
Fibrinolysin
-
Arsenic Trioxide